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fDITORIAL COMMENT
obilizing Cells to
he Injured Myocardium
Novel Rescue Strategy
r an Unwelcome Intrusion?*
ilbur Y. W. Lew, MD, FACC†
an Diego, California
n acute myocardial infarction (MI), salvaging viable myo-
ardium and minimizing adverse ventricular remodeling are
ffective strategies for preserving cardiac function and re-
ucing mortality. Advances in stem cell biology have gen-
rated excitement that this paradigm may be expanded to
nclude transplanting or mobilizing stem cells to repair the
njured myocardium (1). The study by Maekawa et al. (2), in
his issue of the Journal, provides a precautionary tale about
he hazards of mobilizing the wrong cells at the wrong time
n acute MI.
See page 1510
dult stem cells in MI. Adult stem cells (e.g., hemato-
oietic) and progenitor cells can differentiate into mature
issue-specific cells to repair damaged organs, including the
eart (1). In experimental studies, transplanting stem cells
nd progenitor cells into the heart induces angiogenesis and
eplaces damaged myocardium (3). Recent studies indicate
hat hematopoietic stem cells do not transdifferentiate into
ardiac myocytes (4,5). This challenges the concept that any
eneficial effects are related to myocardial regeneration.
Adult stem cell therapy has been applied clinically in
easibility and safety studies. Intracoronary injections of
one marrow-derived or circulating blood-derived progen-
tor cells have been given to patients early (four to nine days)
fter acute MI (6–8). Intramyocardial injections of autolo-
ous skeletal muscle myoblasts and bone marrow-derived
tem cells have been performed in patients with ischemic
eart failure (e.g., 3 to 4 months after MI) (9–11). These
tudies were not designed to evaluate efficacy, but suggest
hat ventricular function may improve, albeit with potential
omplications, such as arrhythmias. Placebo-controlled,
andomized studies are needed to assess the benefits of
herapy, as ventricular function after MI reflects several
actors, including reperfusion, revascularization, myocardial
tunning, and ventricular remodeling.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Cardiology Section, Department of Medicine, Veterans Affairs San
iego Healthcare System and University of California at San Diego, San Diego,
alifornia.obilized stem cells to treat MI. Stem cells circulate in
eripheral blood in low numbers, but possess an enormous
apacity for cell expansion. Granulocyte colony-stimulating
actor (GCSF) mobilizes endothelial progenitor cells into
he peripheral circulation, which can be harvested and
njected intravenously to stimulate angiogenesis and pre-
erve cardiac function after MI (12). Intravenously delivered
tem cells incorporate into peri-infarct regions. This pro-
ides an alternative to direct intramyocardial or intracoro-
ary injections. Mobilizing stem cells from the bone marrow
lso increases delivery to the heart. Experimental studies
upport this approach. In a murine model, stem cell factor
nd GCSF treatment for three to five days after MI
ecreased infarct size, remodeling, and mortality (13,14).
here was evidence of vascular growth and myocardial
egeneration related to the mobilization of stem cells. In a
on-human primate model, treatment increased myocardial
lood flow to the infarct region by increasing angiogenesis
ithout evidence of myocyte regeneration (15). Indeed,
ecent studies demonstrate that adult hematopoietic stem
ells do not transdifferentiate into cardiac myocytes in acute
I (4,5).
Mobilizing endogenous stem cells is an attractive strategy
ecause it obviates the use of exogenous cells and avoids
thical and immunity issues, and granulocyte-macrophage
olony-stimulating factor (GM-CSF) and GCSF are used
linically (e.g., in patients with immunosuppression, after
one marrow transplantation, or to mobilize progenitor cells
nto peripheral blood for harvesting). Homing of endothe-
ial progenitor cells to the heart is enhanced in acute MI
16), suggesting a potential benefit for early therapy. The
ilieu of acute tissue damage contains signaling factors (not
ell characterized) that enhance homing, engraftment, and
ifferentiation of adult stem cells (1,3). Stem cell factor and
CSF therapy are beneficial in experimental acute MI
13–15). In patients with coronary artery disease, GM-CSF
mproves coronary collateral blood flow (17), but this
herapy has not been evaluated in the clinical setting of
cute MI.
obilizing cells with GM-CSF in acute MI. In addition
o stem cells, GM-CSF also mobilizes granulocytes and
onocytes. This may have undesirable effects, because these
ells play a prominent role in inflammatory responses in
cute MI (18). In the study by Maekawa et al. (2) in this
ssue of the Journal, romurtide, an inducer of GM-CSF, was
iven for one week in an experimental model of MI (2).
reatment induced circulating monocytosis and increased
M-CSF expression and infiltration of macrophages into
he infarct site. Treatment had adverse effects on ventricular
emodeling, with greater infarct expansion, poorer left
entricular function, and increased mortality. These results
re consistent with their previous clinical study that associ-
ted peripheral monocytosis with worse left ventricular
unction and remodeling in patients with acute MI (19).Mobilizing neutrophils, macrophages, and monocytes
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Editorial Comment October 6, 2004:1521–2ay be undesirable early during MI. These cells release
oxic substances (e.g., reactive oxygen species) that may
xacerbate inflammation and tissue injury, damage collagen
nd other structural components, and adversely affect ven-
ricular remodeling (18,20). Ventricular remodeling occurs
ver weeks to months with time-dependent changes in key
ediators. Mobilizing cells with GM-CSF during the first
everal days of acute MI adversely affects this process (2),
ut may be effective if delayed after several days (13). This
ay be due to subsidence of acute inflammatory responses.
he optimal timing for stem cell therapy requires under-
tanding the homing signals from damaged tissue, the fate
f transplanted cells (e.g., ability and/or requirement for
tem cells to engraft and transdifferentiate into specific cell
ypes), and the mechanisms of beneficial effects (e.g.,
ngiogenesis, replacing damaged tissue to improve scaffold-
ng, facilitation of normal repair processes).
onclusions. Mobilizing stem cells to treat acute MI has
hown promise in experimental studies, but several issues
eed to be resolved before this can be applied clinically. This
ncludes understanding the mechanisms by which stem cells
mprove tissue repair and how mobilizing inflammatory cells
t the wrong time may exacerbate tissue injury. As future
tudies address the efficacy of this novel therapy, the “do not
arm” principle mandates vigilance to avoid potential adverse
ffects, such as arrhythmias and ventricular remodeling.
eprint requests and correspondence: Dr. Wilbur Y. W. Lew,
ardiology Section 111A, VA San Diego Healthcare System,
350 La Jolla Village Drive, San Diego, California 92161. E-mail:
lew@ucsd.edu.
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